CNDP2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line. This heterogeneous pool carries targeted disruption of the CNDP2 gene via CRISPR/Cas9-mediated gene editing, creating a loss-of-function model without single-cell cloning. The gene encodes a cytosolic non-specific dipeptidase, and its ablation enables functional investigation of dipeptide metabolism. As a polyclonal knockout, it provides an averaged phenotypic readout suitable for diverse assay platforms.
The Raji cell line is a human B lymphoblastoid line isolated from a Burkitt’s lymphoma patient. EBV-positive and growing in suspension, Raji cells retain capabilities for antibody production and antigen presentation, modeling adaptive immune responses. Their origin in a hematopoietic malignancy underpins their utility in cancer and immunology research. This host background positions the CNDP2 knockout for exploring metabolic interactions in B cell biology and lymphoma.
CNDP2 functions as a cytosolic dipeptidase that hydrolyzes carnosine, anserine, and homocarnosine, yielding histidine and beta-alanine. Transcriptionally governed by NF-??B and AP-1, it responds to nutrient-sensing and growth factor cues. Its products modulate mTOR signaling and amino acid transporter activity, while interactions with glutathione precursors connect it to redox regulation. Thus, CNDP2 sits at a metabolic hub linking dipeptide breakdown to cell growth and stress pathways.
In Raji B lymphocytes, CNDP2 disruption disturbs dipeptide catabolism, potentially altering histidine and beta-alanine availability, thereby affecting mTOR-driven proliferation and survival. Because B cells rely on precise metabolic control for antibody synthesis and immune function, this knockout may reveal how amino acid flux influences these processes. Moreover, the Burkitt’s lymphoma context makes it a relevant model for studying metabolic vulnerabilities in leukemia and lymphomas.
Research applications span cancer metabolism (hepatocellular carcinoma, breast cancer, leukemia), B cell biology, dipeptide signaling, drug target validation, and amino acid metabolism. Common assays include Western blot and RT-qPCR for knockout confirmation, proliferation (MTT/BrdU) and apoptosis (Annexin V/PI) tests, metabolomic profiling of dipeptides, flow cytometry for B cell markers, and drug sensitivity studies. For additional details, please contact Ascent Research.
